Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent

被引:34
作者
Schäfer, S
Schmidts, HL
Bleich, M
Busch, AE
Linz, W
机构
[1] Aventis Pharma Deutschland GmbH, Dis Grp Cardiovasc Dis, D-65926 Frankfurt, Germany
[2] Aventis Pharma Deutschland GmbH, DSE Pathol, D-65795 Hattersheim, Germany
关键词
Zucker diabetic fatty rat; diabetic nephropathy; vasopeptidase inhibition; AVE7688;
D O I
10.1038/sj.bjp.0705884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Vasopeptidase inhibition (i.e., the simultaneous inhibition of both angiotensin-converting enzyme ( ACE) and neutral endopeptidase) can ameliorate diabetic nephropathy. We investigated whether this nephroprotection is mediated by the bradykinin B2 receptor. 2 In all, 43 obese Zucker diabetic fatty (ZDF/Gmi-fa/fa) rats aged 21 weeks were separated into four groups and treated for 26 weeks with either placebo, the bradykinin B2 receptor antagonist icatibant (500 mug kg(-1) day(-1) s.c. infusion), the vasopeptidase inhibitor AVE7688 (45 mg kg(-1) day(-1) in chow), or AVE7688 plus icatibant. Nephropathy was assessed as albuminuria at age 31 and 39 weeks, and by histopathologic scoring at the end of the treatment period. 3 All animals had established diabetes mellitus ( blood glucose >20 mmol l(-1)) and marked albuminuria at baseline. Blood glucose was not influenced by any treatment. Icatibant alone did not influence albuminuria (8.6 +/- 1.6 vs placebo 9.5 +/- 1.3 mg kg(-1) h(-1)). AVE7688 reduced albuminuria at week 31 markedly to 1.1 +/- 0.1 mg kg(-1) h(-1) and reduced glomerular and tubulo-interstitial kidney damage at week 47. In the AVE7688 plus icatibant group, proteinuria was significantly higher than in the AVE7688 only group (2.0 +/- 0.6 mg kg(-1) h(-1)), but still reduced compared to placebo. In addition, icatibant partly antagonized the tubulo-interstitial protection mediated by AVE7688. 4 We conclude that vasopeptidase inhibition provides nephroprotection in rats with type II diabetic nephropathy, which is partly mediated by bradykinin B2 receptor activation.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 29 条
[1]   Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats [J].
Amann, K ;
Gassmann, P ;
Buzello, M ;
Orth, SR ;
Törnig, J ;
Gross, ML ;
Magener, A ;
Mall, G ;
Ritz, E .
KIDNEY INTERNATIONAL, 2000, 58 (01) :153-161
[2]   Physiologic consequences of vasopeptidase inhibition in humans:: Effect of sodium intake [J].
Azizi, M ;
Lamarre-Cliche, M ;
Labatide-Alanore, A ;
Bissery, A ;
Guyene, TT ;
Ménard, J .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10) :2454-2463
[3]   Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo [J].
Bäcklund, T ;
Palojoki, E ;
Grönholm, T ;
Eriksson, A ;
Vuolteenaho, O ;
Laine, M ;
Tikkanen, I .
PHARMACOLOGICAL RESEARCH, 2001, 44 (05) :411-418
[4]   Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins - A bradykinin-dependent mechanism [J].
Berkenboom, G ;
Langer, I ;
Carpentier, Y ;
Grosfils, K ;
Fontaine, J .
HYPERTENSION, 1997, 30 (03) :371-376
[5]   Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction [J].
Blais, C ;
Lapointe, N ;
Rouleau, JL ;
Clément, R ;
Gervais, N ;
Geadah, D ;
Adam, A .
PEPTIDES, 2001, 22 (06) :953-962
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]   Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure [J].
Chen, HH ;
Lainchbury, JG ;
Matsuda, Y ;
Harty, GJ ;
Burnett, JC .
HYPERTENSION, 2001, 38 (02) :187-191
[8]   Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy [J].
Davis, BJ ;
Johnston, CI ;
Burrell, LM ;
Burns, WC ;
Kubota, E ;
Cao, Z ;
Cooper, ME ;
Allen, TJ .
DIABETOLOGIA, 2003, 46 (07) :961-971
[9]  
Gerstein HC, 2000, LANCET, V355, P253
[10]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IMPROVES CARDIAC-FUNCTION - ROLE OF BRADYKININ [J].
GOHLKE, P ;
LINZ, W ;
SCHOLKENS, BA ;
KUWER, I ;
BARTENBACH, S ;
SCHNELL, A ;
UNGER, T .
HYPERTENSION, 1994, 23 (04) :411-418